FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955244039> ?p ?o ?g. }

• W2955244039 endingPage "3207" @default.
• W2955244039 startingPage "3207" @default.
• W2955244039 abstract "Abstract The unprecedented success of chimeric antigen receptor (CAR) and monoclonal antibody (mAb) -based immune-therapies has provided a clear indication that a system as complex as human immunity can be harnessed, even enhanced, toward a growing number of hematological cancers. Here we describe pre-clinical progress to develop a multi-functional induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cell platform that combines engineered longevity with CAR and mAb-based modalities to leverage the intrinsic polyfunctionality of NK cells. As frontrunners of immune surveillance, NK cells employ a diverse array of germline encoded receptors in distinct combinations, which engage multiple signaling pathways to deliver potent effector responses that can be directed toward tumor cells, drive rapid proliferation, and pave the way for recruitment of adaptive immunity. Specific engagement of multiple signaling pathways was achieved in iNK cells through design of an NK cell-centric CAR combining the transmembrane domain of activating receptor NKG2D with intracellular signaling domains of 2B4 and CD3ζ. Recombining an anti-CD19 scFv onto this signaling platform, CAR modified iNK cells produced specific in vitro recognition of CD19+ B cell lymphoma cells in short term and long term cytotoxicity assays (84% vs 40% clearance of tumor cells at 60H, p&lt;0.001). Further introduction of a fusion receptor consisting of Interleukin-15 (IL15) with IL15 receptor α, enabling autonomous IL15 stimulation, greatly improved iNK longevity and functional persistence in animal models. Moreover, iNK cells modified with IL15 fusion receptor showed enhanced functional maturation including KIR expression and effector molecules such as granzyme B ( ≥2 fold). While iNK cells with anti-CD19 CAR delayed tumor progression in vivo prior to relapse, iNK cells engineered with anti-CD19 CAR and IL15/IL15 receptor were curative against B cell lymphoma, (p&lt;0.002). Expression of CAR and IL15 fusion receptor was then combined with a third modality, a high affinity CD16a receptor modified to prevent proteolytic cleavage (hnCD16). These multifunctional iNK cells demonstrated enhanced directed cytotoxicity in vitro in combination with rituximab against CD19+ targets (&gt;99% vs 90% clearance of tumor cells) and CD19- targets (&gt;99% vs 50% clearance of tumor cells by iNK with anti-CD19 CAR alone, p&lt;0.0001), revealing a unique opportunity to combine CAR with a universal targeting modality to mitigate antigen escape and address heterogeneity in the tumor population by a multi-node targeting strategy. The resulting product, FT519, is designed to provide a flexible, potent and persistent engineered immune cell that utilizes the intrinsic versatility of NK cells to enable a highly effective combination therapy in a single, standardized, scalable, off-the-shelf platform. Citation Format: Jode Goodridge, Sajid Mahmood, Huang Zhu, Svetlana Gaidarova, Robert Blum, Ryan Bjordahl, Frank Cichocki, Hui-Yi Chu, Greg Bonello, Tom Lee, Brian Groff, Karl-Johan Malmberg, Bruce Walcheck, Jeffrey Miller, Dan Kaufman, Bahram Valamehr. Preclinical development of first-of-kind dual-targeted off-the-shelf CAR-NK cell product with engineered persistence for an effective treatment of B cell malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3207." @default.
• W2955244039 created "2019-07-12" @default.
• W2955244039 creator A5002793798 @default.
• W2955244039 creator A5008300500 @default.
• W2955244039 creator A5011430525 @default.
• W2955244039 creator A5014180019 @default.
• W2955244039 creator A5022682897 @default.
• W2955244039 creator A5023014242 @default.
• W2955244039 creator A5025807763 @default.
• W2955244039 creator A5027151969 @default.
• W2955244039 creator A5027299607 @default.
• W2955244039 creator A5031074371 @default.
• W2955244039 creator A5032499388 @default.
• W2955244039 creator A5054016372 @default.
• W2955244039 creator A5061606756 @default.
• W2955244039 creator A5070964738 @default.
• W2955244039 creator A5086861101 @default.
• W2955244039 creator A5090528267 @default.
• W2955244039 date "2019-07-01" @default.
• W2955244039 modified "2023-09-27" @default.
• W2955244039 title "Abstract 3207: Preclinical development of first-of-kind dual-targeted off-the-shelf CAR-NK cell product with engineered persistence for an effective treatment of B cell malignancies" @default.
• W2955244039 doi "https://doi.org/10.1158/1538-7445.am2019-3207" @default.
• W2955244039 hasPublicationYear "2019" @default.
• W2955244039 type Work @default.
• W2955244039 sameAs 2955244039 @default.
• W2955244039 citedByCount "0" @default.
• W2955244039 crossrefType "journal-article" @default.
• W2955244039 hasAuthorship W2955244039A5002793798 @default.
• W2955244039 hasAuthorship W2955244039A5008300500 @default.
• W2955244039 hasAuthorship W2955244039A5011430525 @default.
• W2955244039 hasAuthorship W2955244039A5014180019 @default.
• W2955244039 hasAuthorship W2955244039A5022682897 @default.
• W2955244039 hasAuthorship W2955244039A5023014242 @default.
• W2955244039 hasAuthorship W2955244039A5025807763 @default.
• W2955244039 hasAuthorship W2955244039A5027151969 @default.
• W2955244039 hasAuthorship W2955244039A5027299607 @default.
• W2955244039 hasAuthorship W2955244039A5031074371 @default.
• W2955244039 hasAuthorship W2955244039A5032499388 @default.
• W2955244039 hasAuthorship W2955244039A5054016372 @default.
• W2955244039 hasAuthorship W2955244039A5061606756 @default.
• W2955244039 hasAuthorship W2955244039A5070964738 @default.
• W2955244039 hasAuthorship W2955244039A5086861101 @default.
• W2955244039 hasAuthorship W2955244039A5090528267 @default.
• W2955244039 hasConcept C109316439 @default.
• W2955244039 hasConcept C202751555 @default.
• W2955244039 hasConcept C203014093 @default.
• W2955244039 hasConcept C2777701055 @default.
• W2955244039 hasConcept C2778867473 @default.
• W2955244039 hasConcept C3875195 @default.
• W2955244039 hasConcept C502942594 @default.
• W2955244039 hasConcept C55493867 @default.
• W2955244039 hasConcept C86803240 @default.
• W2955244039 hasConcept C8891405 @default.
• W2955244039 hasConcept C95444343 @default.
• W2955244039 hasConceptScore W2955244039C109316439 @default.
• W2955244039 hasConceptScore W2955244039C202751555 @default.
• W2955244039 hasConceptScore W2955244039C203014093 @default.
• W2955244039 hasConceptScore W2955244039C2777701055 @default.
• W2955244039 hasConceptScore W2955244039C2778867473 @default.
• W2955244039 hasConceptScore W2955244039C3875195 @default.
• W2955244039 hasConceptScore W2955244039C502942594 @default.
• W2955244039 hasConceptScore W2955244039C55493867 @default.
• W2955244039 hasConceptScore W2955244039C86803240 @default.
• W2955244039 hasConceptScore W2955244039C8891405 @default.
• W2955244039 hasConceptScore W2955244039C95444343 @default.
• W2955244039 hasIssue "13_Supplement" @default.
• W2955244039 hasLocation W29552440391 @default.
• W2955244039 hasOpenAccess W2955244039 @default.
• W2955244039 hasPrimaryLocation W29552440391 @default.
• W2955244039 hasRelatedWork W1986985515 @default.
• W2955244039 hasRelatedWork W1996150995 @default.
• W2955244039 hasRelatedWork W2089899325 @default.
• W2955244039 hasRelatedWork W2145948646 @default.
• W2955244039 hasRelatedWork W3029001555 @default.
• W2955244039 hasRelatedWork W3032483461 @default.
• W2955244039 hasRelatedWork W3086411580 @default.
• W2955244039 hasRelatedWork W3212282404 @default.
• W2955244039 hasRelatedWork W4292999382 @default.
• W2955244039 hasRelatedWork W4353087022 @default.
• W2955244039 hasVolume "79" @default.
• W2955244039 isParatext "false" @default.
• W2955244039 isRetracted "false" @default.
• W2955244039 magId "2955244039" @default.
• W2955244039 workType "article" @default.